BG
SMMT icon

Bellevue Group’s Summit Therapeutics SMMT Stock Holding History

Bellevue Group’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-10,000
Closed -$219K – 173
2024
Q3 		$219K Buy
+10,000
New +$140K ﹤0.01% 146

Other funds holding SMMT

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return

Bellevue Group's SMMT Position: Q2 2026 in Review

Bellevue Group reduced its Summit Therapeutics (SMMT) stake by 3.7% in Q2 2026, selling an estimated $10.3K and leaving 15,279 shares worth $223K. The position accounts for ﹤0.01% of the portfolio, ranked #125.

Bellevue Group first reported a position in SMMT in Q3 2024 and has held it in 8 quarters since. The position peaked at $3.04M in Q4 2024. 242 funds tracked by Wall St. Rank hold SMMT as of Q2 2026.

  • Bellevue Group held 15,279 shares of Summit Therapeutics worth $223K as of Q2 2026.
  • Bellevue Group sold 579 Summit Therapeutics shares in Q2 2026, an estimated $10.3K.
  • Summit Therapeutics made up ﹤0.01% of Bellevue Group's portfolio in Q2 2026, its #125 holding.
  • Bellevue Group first reported a position in Summit Therapeutics in Q3 2024 and has held it in 8 quarters since.
  • Bellevue Group's Summit Therapeutics position peaked at $3.04M in Q4 2024.
  • 242 funds tracked by Wall St. Rank held Summit Therapeutics as of Q2 2026.

Based on Bellevue Group's 13F filing for Q2 2026, filed 14 Aug 2026.